Zolantidine dimaleatePotent, centrally active H2 antagonist CAS# 104076-39-3 |
- CEP-32496
Catalog No.:BCC1079
CAS No.:1188910-76-0
- Sorafenib
Catalog No.:BCN2174
CAS No.:284461-73-0
- Vemurafenib (PLX4032, RG7204)
Catalog No.:BCC1269
CAS No.:918504-65-1
- BRAF inhibitor
Catalog No.:BCC1436
CAS No.:918505-61-0
- PLX-4720
Catalog No.:BCC1280
CAS No.:918505-84-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 104076-39-3 | SDF | Download SDF |
PubChem ID | 11957725 | Appearance | Powder |
Formula | C30H35N3O9S | M.Wt | 613.68 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water | ||
Chemical Name | (Z)-but-2-enedioic acid;N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]-1,3-benzothiazol-2-amine | ||
SMILES | C1CCN(CC1)CC2=CC(=CC=C2)OCCCNC3=NC4=CC=CC=C4S3.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O | ||
Standard InChIKey | IECBEVAUEBZJCF-SPIKMXEPSA-N | ||
Standard InChI | InChI=1S/C22H27N3OS.2C4H4O4/c1-4-13-25(14-5-1)17-18-8-6-9-19(16-18)26-15-7-12-23-22-24-20-10-2-3-11-21(20)27-22;2*5-3(6)1-2-4(7)8/h2-3,6,8-11,16H,1,4-5,7,12-15,17H2,(H,23,24);2*1-2H,(H,5,6)(H,7,8)/b;2*2-1- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | A potent, selective and brain penetrating H2 receptor antagonist. |
Zolantidine dimaleate Dilution Calculator
Zolantidine dimaleate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.6295 mL | 8.1476 mL | 16.2951 mL | 32.5903 mL | 40.7378 mL |
5 mM | 0.3259 mL | 1.6295 mL | 3.259 mL | 6.5181 mL | 8.1476 mL |
10 mM | 0.163 mL | 0.8148 mL | 1.6295 mL | 3.259 mL | 4.0738 mL |
50 mM | 0.0326 mL | 0.163 mL | 0.3259 mL | 0.6518 mL | 0.8148 mL |
100 mM | 0.0163 mL | 0.0815 mL | 0.163 mL | 0.3259 mL | 0.4074 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Atipamezole hydrochloride
Catalog No.:BCC7521
CAS No.:104075-48-1
- Cyclo(Ile-Val)
Catalog No.:BCN2410
CAS No.:104068-43-1
- Rehmapicroside
Catalog No.:BCN2884
CAS No.:104056-82-8
- 3',5'-Diprenylgenistein
Catalog No.:BCN3572
CAS No.:104055-80-3
- Dihydroobovatin
Catalog No.:BCN3982
CAS No.:104055-79-0
- Quinovic acid 3-O-alpha-L-rhamnopyranoside
Catalog No.:BCN1636
CAS No.:104055-76-7
- LP533401 hcl
Catalog No.:BCC6377
CAS No.:1040526-12-2
- Trospium chloride
Catalog No.:BCC4582
CAS No.:10405-02-4
- 8alpha-Methacryloyloxybalchanin
Catalog No.:BCN4756
CAS No.:104021-39-8
- Tussilagone
Catalog No.:BCN2770
CAS No.:104012-37-5
- Cinnamaldehyde
Catalog No.:BCN6241
CAS No.:104-55-2
- Cinnamyl alcohol
Catalog No.:BCN4967
CAS No.:104-54-1
- Fmoc-D-Glu(OtBu)-OH
Catalog No.:BCC3496
CAS No.:104091-08-9
- SR 95531 hydrobromide
Catalog No.:BCC6997
CAS No.:104104-50-9
- Kadsuric acid 3-methylester
Catalog No.:BCN3186
CAS No.:1041070-16-9
- Phellodendrine chloride
Catalog No.:BCN5934
CAS No.:104112-82-5
- Eldecalcitol
Catalog No.:BCC1548
CAS No.:104121-92-8
- Peramivir Trihydrate
Catalog No.:BCC4956
CAS No.:1041434-82-5
- Kuguaglycoside C
Catalog No.:BCN3276
CAS No.:1041631-93-9
- MitoPY1
Catalog No.:BCC6177
CAS No.:1041634-69-8
- Alpinoid D
Catalog No.:BCN3593
CAS No.:1041740-13-9
- Stanozolol
Catalog No.:BCC9154
CAS No.:10418-03-8
- 10-Nitro-camptothecin
Catalog No.:BCN2581
CAS No.:104195-61-1
- Estriol 3,17-dihexanoate
Catalog No.:BCN2238
CAS No.:104202-96-2
A role for histamine and H2-receptors in opioid antinociception.[Pubmed:2547933]
J Pharmacol Exp Ther. 1989 Aug;250(2):476-84.
To investigate the role of brain H2-receptors in opioid antinociceptive mechanisms, the effects of several antagonists of histamine H2-receptors were determined on morphine (MOR)-induced antinociception, opioid-mediated footshock-induced antinociception (FSIA) and on other opiate effects in rats. Zolantidine dimaleate (ZOL), the first brain-penetrating H2 antagonist (0.03-1.6 mumol/kg s.c.) caused a dose-related inhibition of MOR antinociception in both the tail-flick and hot-plate tests, with no effect on base-line responding. ZOL also inhibited opioid FISA with a similar potency. MOR-induced locomotor activity was also reduced by ZOL, but no effect was seen on MOR-induced hyperthermia, catalepsy or lethality. ZOL (10(-5) M) was inactive at mu, delta or kappa opioid receptors and showed at least 35-fold higher affinity at the H2-receptor than at receptors for serotonin, dopamine, norepinephrine or acetylcholine in brain. To clarify further the role of H2-receptors in ZOL's antiopiate activity, the potencies of seven structural congeners of ZOL were determined on the H2-receptor and on MOR antinociception. Over 3 orders of magnitude, the rank order of potencies of the compounds for inhibiting MOR antinociception was highly correlated with their potencies as H2 antagonists. Cimetidine, unlike other H2 antagonists, potentiated MOR antinociception, potentiated opioid FSIA and increased brain MOR levels, actions that are not likely to be due to blockade of H2-receptors. These findings strongly suggest that stimulation of opioid receptors leads to antinociception by mechanisms that include activation of brain H2-receptors.
Actions of the brain-penetrating H2-antagonist zolantidine on histamine dynamics and metabolism in rat brain.[Pubmed:3202904]
Biochem Pharmacol. 1988 Dec 15;37(24):4707-11.
The effects of zolantidine, the first brain-penetrating H2-receptor antagonist, on the brain levels of histamine (HA) and the HA metabolite tele-methylhistamine (t-MH), the activity of histamine methyltransferase (HMT) and the brain HA turnover rates were investigated in rats. Zolantidine dimaleate (0.1 to 100 mg/kg, s.c.) had no effect on whole brain levels of HA or t-MH and no effect on brain HMT activity, when measured 30 min after administration. Furthermore, brain t-MH levels in pargyline-treated animals were unaffected by zolantidine (0.1 to 25 mg/kg), indicating the absence of an effect on brain HA turnover. In vitro, zolantidine was a potent competitive inhibitor of both brain and kidney HMT, with Ki values of 2.3 and 2.7 microM respectively. These results show that, despite the ability of zolantidine to inhibit HMT in vitro, large doses of this drug did not alter brain HA methylation or turnover in vivo, and they imply that blockade of post-synaptic H2-receptors does not change brain HA dynamics.
Cardiac and gastric effects of histamine H2 receptor antagonists: no evidence for a correlation between lipophilicity and receptor affinity.[Pubmed:8842448]
Br J Pharmacol. 1996 Aug;118(7):1813-21.
1. A series of histamine H2 receptor antagonists with different lipophilicity were tested in cardiac and gastric assays in order to reveal possible differences in receptor affinity. Lipophilicity of the compounds was expressed as CLOG P (theoretically-determined logarithm of octanol:water partition coefficient) and log k' (logarithm of capacity factor, experimentally-determined by reverse-phase high performance liquid chromatography). 2. Aminopotentidine (APT) and iodoaminopotentidine (I-APT), which are both lipophilic compounds, behaved as insurmountable antagonists of histamine responses in rat isolated gastric fundus (pKB = 6.20 +/- 0.16 and 6.89 +/- 0.19, respectively) and guinea-pig isolated papillary muscle (pKB = 6.34 +/- 0.37 and 6.81 +/- 0.26, respectively). They were approximately as effective as ranitidine (RAN) in reducing histamine-induced acid secretion in the anaesthetized rat, ID50 values being 0.018 +/- 0.02, 0.020 +/- 0.03 and 0.036 +/- 0.01 mumol kg-1 i.v. for APT, I-APT and RAN, respectively. Both APT and I-APT had a significantly longer duration of action than RAN. 3. The hydrophilic compound, SK&F 92857, was inactive up to 10 microM in modifying histamine-induced acid secretion in the isolated rat stomach. In the papillary muscle, low concentrations (0.1-1 microM) of this compound produced a competitive antagonism of the histamine responses (pA2 value = 7.38 +/- 0.11), while a higher concentration (10 microM) significantly reduced the maximal response to histamine. 4. RAN competitively antagonized histamine effects with a comparable affinity in cardiac and gastric preparations (pA2 values were 6.42 +/- 0.09 and 6.78 +/- 0.38 in heart and stomach, respectively). 5. Results obtained in this study clearly showed that the discrepancies between gastric and cardiac effects observed for some H2 antagonists are not explained solely by differences in lipophilicity of compounds. Moreover, the significant correlation found between CLOG P and log k' parameter, which takes into account, besides their lipophilicity, the ionization of the molecules, suggests that ionization has a similar influence for all the molecules on the partition between the lipophilic and aqueous phase.
Activity of the new histamine H2-receptor antagonist zolantidine at cardiac and gastric H2-receptors.[Pubmed:7907797]
Pharmacology. 1994 Feb;48(2):69-76.
The effect of the new histamine H2-receptor antagonist zolantidine was studied in different cardiac and gastric H2-receptor assays in comparison with ranitidine. Zolantidine (0.1-10 mumol/l) competitively antagonized the positive effects of histamine in the spontaneously beating guinea pig atria and in the electrically stimulated guinea pig papillary muscle (pA2 values were 6.98 and 6.78, respectively). At the highest concentrations zolantidine also reduced basal heart rate and cardiac contractility. In the isolated rat gastric fundus zolantidine up to 100 mumol/l did not modify histamine-induced acid secretion; it was similarly ineffective against dimaprit-induced acid secretion in the gastric fistula of conscious cats (up to 3 mumol/kg i.v.) and against histamine in the anesthetized rat with lumen-perfused stomach (up to 30 mumol/kg i.v.). In all these gastric secretory models ranitidine, as expected, antagonized histamine H2-receptor-mediated responses, showing a potency comparable to that found in cardiac preparations (pA2 values were 6.84, 6.38 and 6.78 in the atria, papillary muscle and gastric fundus, respectively). These data clearly showed that zolantidine is a very peculiar histamine H2-receptor antagonist, capable of distinguishing between cardiac and gastric H2-receptors; however, it still has to be elucidated whether this depends on a true heterogeneity in the histamine H2-receptor population or on the physicochemical properties of the drug.
Zolantidine (SK&F 95282) is a potent selective brain-penetrating histamine H2-receptor antagonist.[Pubmed:2894879]
Br J Pharmacol. 1988 Jan;93(1):69-78.
1. The novel benzthiazole derivative zolantidine (SK&F 95282) is a potent antagonist of histamine at H2-receptors in guinea-pig atrium and rat uterus. Only apparent pA2 values of 7.46 and 7.26 respectively could be calculated since the slopes of the Schild plots were significantly less than unity. 2. Zolantidine is equally potent as an antagonist at histamine H2-receptors in guinea-pig brain. The compound inhibited histamine stimulated adenylate cyclase (pKi 7.3) and dimaprit stimulated adenosine 3':5'-cyclic monophosphate (cyclic AMP) accumulation (approx pA2 7.63), and competed with [3H]-tiotidine binding (pKi 7.17). 3. Zolantidine is at least 30 fold more potent at H2-receptors than at other peripheral and central receptors investigated. 4. Infusion of zolantidine into rats produces a brain concentration greater than the plateau blood concentration (brain/blood ratio 1.45). 5. Zolantidine is thus characterized as a potent selective brain-penetrating H2-receptor antagonist, and will be a valuable pharmacological tool for investigating possible physiological and pathological roles for histamine in the central nervous system.